No human data · Grade D
Testagen
Testagen (Khavinson Tetrapeptide)
Score
46 / 100
Structure
Tetrapeptide (KEDG)
Origin
Khavinson (Russia)
Status
Preclinical / claims
TL;DR
01
A synthetic tetrapeptide (Lys-Glu-Asp-Gly, 'KEDG') from Vladimir Khavinson's bioregulator program, marketed as supporting gonadal/reproductive function.
02
Like the other Khavinson peptides, its proposed mechanism is entering the cell nucleus and binding DNA sequence-specifically to influence gene activity.
03
There are no human trials of any kind for testagen — the reproductive/testosterone-support claims are unproven, so it is rated No Human Data.
04
The 'gene regulation by a short peptide' basis is scientifically contentious, and the specific gonadal claims are especially thinly supported.
05
It is not approved and is sold as a research chemical.
Human trials
None
no clinical data
Gonadal/testosterone claims
Unproven
no supporting human data
Mechanism (in vitro)
DNA-sequence binding
nuclear penetration
Evidence source
Khavinson group
not independently replicated
Approval
None
research chemical
Part 01 · How it works
Mechanism.
Testagen is a four-amino-acid Khavinson peptide sold on the promise of supporting the gonads and testosterone. The family's proposed mechanism is that these tiny peptides enter cells and the nucleus and bind DNA at specific sequences to tune gene activity. For testagen specifically, that mechanism is shown only at the in-vitro DNA-binding level, and there are no human studies at all backing the reproductive claims. Both the general 'short peptide reprograms genes' idea and the specific gonadal-support claim are weakly supported.
A four-letter 'instruction' marketed for testosterone support — but the only real evidence is that it can stick to DNA in a test tube, with nothing in humans behind the hormonal claims.
Bioregulator tetrapeptide
Lys-Glu-Asp-Gly (KEDG); part of the Khavinson short-peptide program.
Nuclear penetration / DNA binding
In vitro, penetrates the nucleus and binds specific DNA sequences (e.g., CAG sites).
Gonadal claims
Marketed for gonadal/reproductive support; no human data supports this.
Evidence stage
In vitro only for testagen specifically; no human trials.
Part 02 · Dosing & administration
How it's taken.
No validated doseNo independently validated human dosing exists for Testagen. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Dose
No validated dose
Khavinson tetrapeptide bioregulator (KEDG). No FDA-approved indication and no validated human dosing. Vendor 'Cytogen' capsule products and older Russian research describe inconsistent amounts; none is supported by human efficacy data.
·
Any doses referenced are from Russian protocols, not validated instructions.
·
No human dosing data.
·
No purity/dose guarantee in research-chemical supply.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Human tolerability
No human data.
Unknown
Serious · rare
Long-term human safety
No human safety data.
Unknown
Product-quality risk
Research-chemical supply; purity/dose unknown.
Source-dependent
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to testagen or any component
×
Hormone-sensitive cancers (theoretical concern with any peptide affecting reproductive axis)
Relative · discuss first
!
Anyone seeking a proven testosterone/gonadal therapy — no human evidence supports testagen
!
Pregnancy or breastfeeding — no data
!
Hormone-sensitive conditions — unstudied effects
Interactions
Testosterone replacement therapy
Testagen is a bioregulator peptide targeting testicular function; may have additive effects on testosterone levels
Moderate
Aromatase inhibitors
Changes in testosterone production may alter estrogen balance; monitor hormone levels
Minor
GnRH agonists/antagonists
Testagen may interact with hypothalamic-pituitary-gonadal axis signaling
Moderate
Labs to monitor
Total and Free Testosterone
Baseline and at end of cycle
Testagen purportedly supports testicular function
LH and FSH
Baseline and at end of cycle
Monitor gonadotropin levels
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
General metabolic safety
CBC with Differential
Baseline and every 3 months
General safety monitoring
Part 04 · Evidence
How strong is the evidence?
46
Grade D
Grade D, No Human Data. Testagen's only concrete evidence is in-vitro DNA binding shared across the Khavinson peptides; its specific gonadal/testosterone claims have no human support, and the underlying mechanism is contested.
Mechanistic plausibility
In-vitro DNA binding shown; specific hormonal gene regulation by a tetrapeptide is unproven and contentious.
48
Human evidence
No human trials; gonadal claims unsupported.
15
Safety & tolerability
No human safety data.
52
Durability
No human outcome data.
45
Independence
Evidence concentrated in the originating group.
35
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2011
Biochemistry (Moscow) Flagged
Short peptides (incl. testagen) penetrate the nucleus and bind DNA sequence-specifically
Testagen and related Khavinson peptides entered human cell nuclei and bound specific DNA sequences — the shared, in-vitro mechanistic basis for the bioregulator claims. No functional gonadal outcome was demonstrated.
In vitro (HeLa cells + oligonucleotide binding) · Mechanistic in-vitro study; does not support the marketed hormonal claims.
PMID 22117547 ↗
Moderate (in vitro)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
No human data — and the gonadal claims have no support
Mechanism limit Biochemistry (Moscow) · 2011
Testagen has no human trials. Its only concrete evidence is shared in-vitro DNA binding; the specific claim that it supports gonadal function or testosterone is not backed by any human study.
What this means: Marketed for testosterone support with zero human evidence for that effect. There is no reason to expect the hormonal benefit it is sold on.
PMID 22117547 ↗
Part 06 · Cost & access
Where it's available, at what price.
Russia
Marketed (bioregulator)
Sold within the Khavinson bioregulator framework.
Russian market
United States
Not approved
No approved product; research chemical.
Grey-market; unregulated
European Union
Not approved
No approved product.
N/A
United Kingdom
Not approved
No approved product.
N/A
The Peptide Column takes no affiliate commission from any source. Testagen has no human trials and is not approved anywhere; consumer supply is research-grade and unregulated, and its gonadal/testosterone claims have no human support. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Are there any published peer-reviewed human trials of Testagen that have been independently replicated?
02
What are the risks of attempting to influence testosterone production with an uncharacterized peptide?
03
How does this compare to evidence-based interventions for age-related low testosterone?
04
Is the source and purity of Testagen verifiable if obtained from research chemical suppliers?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Short peptides (incl. testagen) penetrate the nucleus and bind DNA sequence-specifically · Biochemistry (Moscow), 2011 · PMID 22117547 ↗
- 02. St. Petersburg Institute of Bioregulation and Gerontology. Khavinson bioregulator program